#United States #Dublin #earnings report #Cardinal Health #Fiscal Year 2025

Cardinal Health Reports Third Quarter Fiscal Year 2025 Results

On May 1, 2025, Cardinal Health (NYSE: CAH) disclosed its financial results for the third quarter of the fiscal year 2025, showcasing resilience amidst evolving market challenges. Despite maintaining revenue at $54.9 billion—indicating no change from the same quarter last year—the company highlighted a 19% revenue boost when excluding a previously communicated customer contract expiration.

Financial Highlights

The fiscal report revealed that Cardinal Health's GAAP operating earnings surged to $730 million, a significant increase from $369 million in the previous fiscal year, marking a 98% rise year-over-year. Consequently, the GAAP diluted earnings per share (EPS) registered at $2.10, up from $1.07, reflecting a 96% increment.

Moreover, the non-GAAP operating earnings increased by 21% to $807 million, while the non-GAAP diluted EPS rose by 13% to $2.35, due to profit growth across all operational segments.

Key figures for Q3 FY25:

• - Revenue: $54.9 billion (flat YoY)
• - Operating earnings: $730 million (up 98%)
• - Non-GAAP operating earnings: $807 million (up 21%)
• - GAAP diluted EPS: $2.10 (up 96%)
• - Non-GAAP diluted EPS: $2.35 (up 13%)

Segment Performance

Pharmaceutical and Specialty Solutions

The Pharmaceutical and Specialty Solutions segment generated revenues of $50.4 billion, remaining essentially flat compared to $50.6 billion reported in the third quarter of fiscal year 2024. Excluding the impact of the customer contract expiration, segment revenue grew by 20%, bolstered by increasing sales of brand and specialty pharmaceuticals.

The segment profit also rose by 14%, reaching $662 million, driven largely by contributions from brand and specialty products along with strong performance from the MSO platforms and generics.

Global Medical Products and Distribution

Revenue in the Global Medical Products and Distribution segment grew by 2% to $3.2 billion. The segment's profit increased notably by 77% to $39 million, attributed to effective cost optimization measures.

Other Segments